LIMR outlicenses to MYNARI Biomedical a blood test to predict acute nausea caused by cancer chemotherapy
The Lankenau Institute for Medical Research (LIMR) signed a licensing agreement in January with MYNARI Biomedical, a biotech startup that will commercialize MyNauseaRisk, a LIMR-developed blood test that reliably and objectively predicts which cancer patients are most likely to experience acute nausea after chemotherapy.
Nausea and vomiting in the days after chemotherapy is a much-feared side effect of treatment, yet not all patients experience such effects equally. For some, nausea is almost non-existent, while for others it is debilitating. Being able to predict which patients are more likely to suffer from delayed chemotherapy-induced nausea—especially delayed nausea after the patient has received chemotherapy and left the clinic—has been a challenge for healthcare providers interested in sparing their cancer patients undue distress and discomfort.
“The MyNauseaRisk blood test helps alert physicians to those particular oncology patients for whom we must prescribe more potent anti-nausea drugs,” said Paul Gilman, MD, director of clinical research at LIMR. “When used in clinical practice, patients are tested prior to starting therapy, thus allowing caregivers the chance to devise an optimal and personalized nausea-prevention regimen.”
Antiemetic drugs, which are given to chemotherapy patients, have their own side effects, including insomnia, constipation and headaches. “Patients whom we have determined from the blood test are at a lower risk of delayed nausea may be treated with a modified regimen, sparing them the ill effects of the anti-nausea medications,” said U. Margaretha Wallon, PhD, assistant professor at LIMR and the lead author of the study whose results led to the test’s development. The W.W. Smith Charitable Trust in West Conshohocken, Pa., funded Dr. Wallon’s clinical research to develop this test.
Results of the clinical trials performed at Main Line Health demonstrated that MyNauseaRisk could correctly classify nearly 90 percent of patients experiencing high nausea sensitivity.
MYNARI Biomedical, based in Fort Washington, Pa., has licensed the test from LIMR. Steve Davis, CEO of MYNARI, has a 25-year background in early-stage companies focused on novel medical innovations, including surgical devices, diagnostic tests and therapeutics. He has significant and diversified experience in all facets of their development.
“Our primary goal is to get the MyNauseaRisk diagnostic test on the market as soon as possible,” said Davis. “In the short term, we hope to work with pharmaceutical companies developing better antiemetic drugs to help them identify patients at risk of nausea from chemotherapy and further validate the test’s efficacy.”
The licensing deal was shepherded to a close by the Office of Innovation at Thomas Jefferson University (Jefferson), a Philadelphia-based professional university with a national reputation for transdisciplinary learning and innovation and which has partnered with LIMR to help manage the commercialization of its growing patent portfolio.
“Dr. Wallon’s MyNauseaRisk technology stood out to me as offering a significant advancement in patient care, so it came as no surprise to me when Steve Davis approached us with interest in partnering with LIMR on its translational development,” said Rose Ritts, PhD, chief innovation officer and executive vice president of innovation at Jefferson. “We are thrilled to have helped connect the players who will advance it to the next important stage of development.”
LIMR administers all of the clinical trials ongoing at Main Line Health. Currently, about 30 cancer clinical trials are recruiting participants. Most of those trials are studying the safety and efficacy of new treatment options. A few, such as MyNauseaRisk, are going beyond those traditional types of trials and are studying strategies that may help patients better manage the side effects of their cancer treatments.
“Most large health systems in our region offer patients access to clinical trials, but our lineup at Main Line Health also includes unique studies whose results may help future patients live more satisfying lives while they battle their cancers,” said George Prendergast, president and CEO of LIMR. “That’s a key differentiating factor and one that we’re confident cancer patients want more of. They don’t want to just survive their cancers—they want to continue to thrive in life.”
About Main Line Health
Founded in 1985, Main Line Health is a not-for-profit health system serving Philadelphia and its suburbs. Main Line Health's commitment — to deliver safe, high-quality, equitable and affordable care for treating and curing disease, playing an important role in prevention and disease management, as well as training physicians and other health care providers — reflects our intent to be the region's premier choice for clinical care, research, and education. A team of more than 13,000 employees and over 3,500 employed and independent physicians and advanced practice providers care for patients throughout Main Line Health.
At Main Line Health's core are four of the region's most respected acute care hospitals — Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital — as well as one of the nation's premier facilities for rehabilitative medicine, Bryn Mawr Rehab Hospital.
Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region's largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care and service, including the prestigious American Hospital Association Quest for Quality Prize, highest tier ratings from the Centers for Medicare & Medicaid Services (CMS) for Overall Hospital Quality and systemwide recognition in the 2023-2024 U.S. News & World Report Best Hospitals rankings. Main Line Health is committed to creating an environment of diversity, respect, equity and inclusion, has proudly received awards in this area and has embraced the American Hospital Association's #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help patients stay healthy and live their best lives.
For more information, visit mainlinehealth.org and connect with us on social media:
About Lankenau Institute for Medical Research
Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR's mission is to improve human health and well-being. Using its ACAPRENEURIALTM model that integrates academic and entrepreneurial approaches, faculty and staff are devoted to advancing innovative new strategies to address formidable medical challenges including cancer, cardiovascular disease, tissue regeneration, gastrointestinal disorders and autoimmune diseases such as diabetes and arthritis. LIMR's principal investigators conduct basic, preclinical and clinical research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.